Citations

Clear

1134 citation(s) found for "Yan, Yan".

Inactivation of Receptor Tyrosine Kinases Reverts Aberrant DNA Methylation in Acute Myeloid Leukemia
Yan, Fei , Pang, Jiuxia, Zhao, Na , Gangat, Naseema , Bode, Ann M. , Al‐Kali, Aref , Litzow, Mark R. , Liu, Shujun , Shen, Na , Wu, Lai‐Chu

Mayo Clinic

Clinical Cancer Research | July 18, 2017 | Volume: 23 | Issue: 20 | Pages: 6254-6266

10.1158/1078-0432.ccr-17-0235 | PMID 28720666 Get It

Abstract Purpose: Receptor tyrosine kinases (RTKs) are frequently deregulated in leukemia, yet the biological consequences of this deregulation remain elusive. The mechanisms underlying aberrant methylation, a hallmark of leukemia, are not fully understood. Here we investigated the role of RTKs in methylation abnormalities and characterized the hypomethylating activities of RTK inhibitors. Experimental Design: Whether and how RTKs regulate expression of DNA methyltransferases (DNMTs), tumor suppressor genes (TSGs) as well as global and gene-specific DNA methylation were examined. The pharmacologic activities and mechanisms of actions of RTK inhibitors in vitro, ex vivo, in mice, and in nilotinib-treated leukemia patients were determined. Results: Upregulation of RTKs paralleled DNMT overexpression in leukemia cell lines and patient blasts. Knockdown of RTKs disrupted, whereas enforced expression increased DNMT expression and DNA methylation. Treatment with the RTK inhibitor, nilotinib, resulted in a reduction of Sp1-dependent DNMT1 expression, the diminution of global DNA methylation, and the upregulation of the p15INK4B gene through promoter hypomethylation in AML cell lines and patient blasts. This led to disruption of AML cell clonogenicity and promotion of cellular apoptosis without obvious changes in cell cycle. Importantly, nilotinib administration in mice and human patients with AML impaired expression of DNMTs followed by DNA hypomethylation, TSG re-expression, and leukemia regression. Conclusions: Our findings demonstrate RTKs as novel regulators of DNMT-dependent DNA methylation and define DNA methylation status in AML cells as a pharmacodynamic marker for their response to RTK-based therapy, providing new therapeutic avenues for RTK inhibitors in overcoming epigenetic abnormalities in leukemia. Clin Cancer Res; 23(20); 6254–66. ©2017 AACR.
Multi‐genic pattern found in rare type of hypopituitarism: a whole‐exome sequencing study of Han Chinese with pituitary stalk interruption syndrome
Guo, Qinghua , Wang, Chengzhi , Qin, Yan , Han, Baiyu, Wang, Anping , Wang, Baoan, Dou, Jingtao , Wu, Xiaosheng , Mu, Yiming , Wang, Cheng-Zhi , Wu, Xiao-Sheng, Wu, Zhiqiang

Mayo Clinic

Journal of Cellular and Molecular Medicine | July 14, 2017 | Volume: 21 | Issue: 12 | Pages: 3626-3632

10.1111/jcmm.13272 | PMID 28707430 Get It

AbstractPituitary stalk interruption syndrome (PSIS) is a rare type of hypopituitarism manifesting various degrees of pituitary hormone deficiency. Although mutations have been identified in some familial cases, the underpinning mechanisms of sporadic patients with PSIS who are in a vast majority remain elusive, necessitating a comprehensive study using systemic approaches. We postulate that other genetic mechanisms may be responsible for the sporadic PSIS. To test this hypothesis, we conducted a study in 24 patients with PSIS of Han Chinese with no family history using whole‐exome sequencing (WES) and bioinformatic analysis. We identified a group of heterozygous mutations in 92% (22 of 24) of the patients, and these genes are mostly associated with Notch, Shh, Wnt signalling pathways. Importantly, 83% (20 of 24) of the patients had more than one mutation in those pathways suggesting synergy of compound mutations underpin the pathogenesis of sporadic PSIS.
Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort
(CCFR), Colon Cancer Family Registry, Rosty, Christophe , Lindor, Noralane M. , Gruber, Stephen B. , Buchanan, Daniel D. , Raskin, Leon , (CCFR), Colon Cancer Family Registry, Guo, Yan Ping , Du, Liping , Clendenning, Mark , Buchanan, Daniel D , Rosty, Christophe

Mayo Clinic

Oncotarget | June 21, 2017 | Volume: 8 | Issue: 55 | Pages: 93450-93463

10.18632/oncotarget.18596 | PMID 29212164 Get It

TARGETABLE FUSIONS OF THE FRK TYROSINE KINASE IN ALK‐NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA
Boddicker, Rebecca L., Dasari, Surendra , Asmann, Yan W. , Knudson, Ryan A., Eckloff, Bruce W., Jen, Jin , Hu, Gangqing , Greipp, Patricia T. , Link, Brian K. , Bennani, N. Nora , Cerhan, James R. , Feldman, Andrew L.

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 59-59

10.1002/hon.2437_45 Get It

Update on Immunohistochemical Analysis in Breast Lesions
Peng, Yan , Butt, Yasmeen M. , Chen, Beiyun, Zhang, Xinmin , Tang, Ping , Tang, Ping

Mayo Clinic

Archives of Pathology & Laboratory Medicine | June 2, 2017 | Volume: 141 | Issue: 8 | Pages: 1033-1051

10.5858/arpa.2016-0482-ra | PMID 28574279 Get It

Context.— The utility of immunohistochemistry (IHC) in breast lesions needs to be updated with exceptions among these lesions. Biomarker studies with IHC in triple-negative breast carcinoma may help develop targeted therapies for this aggressive breast cancer. The distinction of metastatic lung adenocarcinoma to the breast and invasive breast carcinoma has significant prognostic and therapeutic implications. The determination can be challenging because both primary tumors can express estrogen receptor and/or HER2 by IHC, creating a diagnostic dilemma. Objectives.— To provide a practical update on the use of IHC markers in differential diagnoses in breast lesions, including benign, atypical, precancerous, and malignant tumors; to highlight recently published research findings on novel IHC markers in triple-negative breast carcinoma cases; and to reinforce the importance of IHC use as an ancillary tool in distinguishing metastatic lung adenocarcinoma to the breast from primary breast carcinoma using real case examples. Data Sources.— PubMed (US National Library of Medicine, Bethesda, Maryland) literature review and authors' research data and personal experiences were used in this review. Conclusions.— Immunohistochemistry has an important role in making differential diagnoses in breast lesions in morphologically equivocal settings; recognizing IHC expression status in the exceptions among these lesions will aid in the correct diagnosis of challenging breast cases. Studies suggest that androgen receptor, p16, p53, GATA3, and PELP1 may have potential diagnostic, prognostic, and predictive value in triple-negative breast carcinoma cases; these findings may provide insight and a greater understanding of the tumor biology in triple-negative breast carcinomas. In distinguishing metastatic estrogen receptor–positive or HER2+ lung adenocarcinoma to the breast from primary breast carcinoma, napsin A, TTF-1, and GATA3 comprise a useful IHC panel.
Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials
Yan, Fangrong , Mandrekar, Sumithra J. , Yuan, Ying

Mayo Clinic

Clinical Cancer Research | May 25, 2017 | Volume: 23 | Issue: 15 | Pages: 3994-4003

10.1158/1078-0432.ccr-17-0220 | PMID 28546227 Get It

Abstract The primary objective of phase I oncology trials is to find the MTD. The 3+3 design is easy to implement but performs poorly in finding the MTD. A newer design, such as the modified toxicity probability interval (mTPI) design, provides better accuracy to identify the MTD but tends to overdose patients. We propose the keyboard design, an intuitive Bayesian design that conducts dose escalation and de-escalation based on whether the strongest key, defined as the dosing interval that most likely contains the current dose, is below or above the target dosing interval. The keyboard design can be implemented in a simple way, similar to the traditional 3+3 design, but provides more flexibility for choosing the target toxicity rate and cohort size. Our simulation studies demonstrate that compared with the 3+3 design, the keyboard design has favorable operating characteristics in terms of identifying the MTD. Compared with the mTPI design, the keyboard design is safer, with a substantially lower risk of treating patients at overly toxic doses, and has the better precision to identify the MTD, thereby providing a useful upgrade to the mTPI design. Software freely available at http://www.trialdesign.org facilitates the application of the keyboard design. Clin Cancer Res; 23(15); 3994–4003. ©2017 AACR. See related commentary by Paoletti et al., p. 3977
Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
Xochelli, Aliki , Kavakiotis, Ioannis , Agathangelidis, Andreas , Sutton, Lesley-Ann, Minga, Eva, Ntoufa, Stavroula , Tausch, Eugen , Yan, Xiao‐Jie , Plevová, Karla , Boudjogra, Myriam, Rossi, Davide , Davis, Zadie , Navarro, Alba , Sandberg, Yorick , Vojdeman, Fie Juhl , Scarfò, Lydia , Stavroyianni, Niki, Sudarikov, Andrey , Τζένου, Τατιάνα , Karan-Djurašević, Teodora , Catherwood, Mark , Kienle, Dirk, Chatzouli, Maria, Facco, Monica , Bahlo, Jasmin, Pott, Christiane , Pedersen, Lone Bredo , Mansouri, Larry, Smedby, Karin E. , Chu, Charles C. , Giudicelli, Véronique , Lefranc, Marie‐Paule , Juliusson, Gunnar , Anagnostopoulos, Αchilles , Antić, Darko , Trentin, Livio , Montillo, Marco , Niemann, Carsten Utoft , Pospı́šilová, Šárka , Hallek, Michael , Maglaveras, Nikos, Oscier, David , Gaïdano, Gianluca , Jelinek, Diane F., Chouvarda, Ioanna , Darzentas, Nikos , Belessi, Chrysoula, Davi, Frédéric , Hadzidimitriou, Anastasia , Rosenquist, Richard , Ghia, Paolo , Σταματόπουλος, Κώστας , Maglaveras, Nicos , Baliakas, Panagiotis , Sutton, Lesley‐Ann, Shanafelt, Tait D. , Veronese, Silvio , Panagiotidis, Panagiotis T. , Vlahavas, Ioannis P. , Döhner, Hartmut , Langerak, Anton W. , Campo, Elı́as , Chiorazzi, Nicholas , Stilgenbauer, Stephan , Gaidano, Gianluca , Ghia, Paolo , Rosenquist, Richard

Mayo Clinic

Clinical Cancer Research | May 23, 2017 | Volume: 23 | Issue: 17 | Pages: 5292-5301

10.1158/1078-0432.ccr-16-3100 | PMID 28536306 Get It

Abstract Purpose: We sought to investigate whether B cell receptor immunoglobulin (BcR IG) stereotypy is associated with particular clinicobiological features among chronic lymphocytic leukemia (CLL) patients expressing mutated BcR IG (M-CLL) encoded by the IGHV4-34 gene, and also ascertain whether these associations could refine prognostication. Experimental Design: In a series of 19,907 CLL cases with available immunogenetic information, we identified 339 IGHV4-34–expressing cases assigned to one of the four largest stereotyped M-CLL subsets, namely subsets #4, #16, #29 and #201, and investigated in detail their clinicobiological characteristics and disease outcomes. Results: We identified shared and subset-specific patterns of somatic hypermutation (SHM) among patients assigned to these subsets. The greatest similarity was observed between subsets #4 and #16, both including IgG-switched cases (IgG-CLL). In contrast, the least similarity was detected between subsets #16 and #201, the latter concerning IgM/D-expressing CLL. Significant differences between subsets also involved disease stage at diagnosis and the presence of specific genomic aberrations. IgG subsets #4 and #16 emerged as particularly indolent with a significantly (P < 0.05) longer time-to-first-treatment (TTFT; median TTFT: not yet reached) compared with the IgM/D subsets #29 and #201 (median TTFT: 11 and 12 years, respectively). Conclusions: Our findings support the notion that BcR IG stereotypy further refines prognostication in CLL, superseding the immunogenetic distinction based solely on SHM load. In addition, the observed distinct genetic aberration landscapes and clinical heterogeneity suggest that not all M-CLL cases are equal, prompting further research into the underlying biological background with the ultimate aim of tailored patient management. Clin Cancer Res; 23(17); 5292–301. ©2017 AACR.
Cybersecurity and medical devices: A practical guide for cardiac electrophysiologists
Ransford, Benjamin, Kramer, Daniel B. , Kune, Denis Foo, Medeiros, Julio Auto de, Crawford, Thomas , Fu, Kevin , Auto de Medeiros, Julio, Chen, Yan , Xu, Wenyuan

Mayo Clinic

Pacing and Clinical Electrophysiology | May 17, 2017 | Volume: 40 | Issue: 8 | Pages: 913-917

10.1111/pace.13102 | PMID 28512774 Get It

AbstractMedical devices increasingly depend on software. While this expands the ability of devices to perform key therapeutic and diagnostic functions, reliance on software inevitably causes exposure to hazards of security vulnerabilities. This article uses a recent high‐profile case example to outline a proactive approach to security awareness that incorporates a scientific, risk‐based analysis of security concerns that supports ongoing discussions with patients about their medical devices.